(2022). Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study. J R Soc Med, 1410768221131897. http://doi.org/10.1177/01410768221131897.
(2022). Frequency and severity of respiratory infections prior to COPD diagnosis and risk of subsequent postdiagnosis COPD exacerbations and mortality: EXACOS-UK health care data study. Thorax. http://doi.org/10.1136/thorax-2022-219039.
(2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437.
(2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799.
(2022). A retrospective cohort study measured predicting and validating the impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. http://doi.org/10.1016/j.kint.2022.05.015.
(2022). Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis, 17, 427-437. http://doi.org/10.2147/copd.s346591.
(2011). Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf. http://doi.org/10.2165/11594540-000000000-00000.
(2020). Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Res. http://doi.org/10.1183/23120541.00188-2020.